General Pharmaceutical Council



Right-touch regulation

Professional Standards Authority (PSA)

10 March 2025 – 2 May 2025

GPhC response

We welcome the PSA's decision to review and update Right Touch Regulation, particularly in light of the many changes and developments which have impacted the delivery of healthcare over the last ten years.

We do not have detailed comments at this stage of the review, but would like to make the following points:

- We will be interested to see how the development of the updated document aligns with the smarter regulation principles expected from the Better Regulation Executive and whether/how this review ties in with the ongoing review of the Standards of Good Regulation.
- We support an increased focus on collaboration as we are of the view that effective collaboration, (in the context of health and social care being much more integrated, joined up and interdependent) is essential and so regulation needs to be likewise. This reflects a priority we have identified in preparing our next five-year strategic plan.
- We also support a shift in focus in RTR3, moving more to putting forward suggestions as to how the principles can be applied, with the continued use of examples and case studies.
- We welcome the prospect of RTR3 taking account of current challenges facing healthcare and regulation such as the increasing use of AI in healthcare and the need to balance consistency and differences, such as those which exist between the four nations, when designing regulatory systems

If you would like to discuss the points raised in this response, or any other aspect of the GPhC's work, please do not hesitate to contact us.

General Pharmaceutical Council

2 May 2025